TheEdgeResearch
Home / Stocks / FITY

Fifty 1 Labs, Inc. (FITY)

OTC Healthcare Drug Manufacturers - Specialty & Generic
$0.00 ▲ +0.00%
Market Cap
$171,564
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
2.78
52-Wk Range
0.0002-0.0047
CEO
Joel Gagnier
Country
US
Currency
USD

Fifty 1 Labs, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Melbourne, FL, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $171,564. On trailing twelve-month figures it carries a trailing P/E of -4.25, a net margin of -37262.8%. Its beta of 2.78 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-4.25
Price / Sales
1159.22
Price / Book
-1.23
EV / EBITDA
-6.15
Gross margin
29.1%
Operating margin
-37262.8%
Net margin
-37262.8%
Return on equity
Debt / equity
-0.88
Current ratio
0.00
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
10
IPO date
2005-07-18
Headquarters
Melbourne, FL, US
About Fifty 1 Labs, Inc.

Fifty 1 Labs, Inc. is a Nevada-based holding company that has shifted its focus to biotechnology and telehealth, centering on peptide science for musculoskeletal health, recovery, and performance. The company utilizes AI-driven research and aims to develop a telehealth platform for personalized peptide therapies. Formerly involved in automotive finance, the company is now pursuing growth in the functional medicine and life sciences sectors.

Comparable companies

Fifty 1 Labs, Inc. is most often compared with the following Healthcare names:

AIJTYATNPQCNERCSOLFNNZFIHAISVLTSVTPFTNBITWNE
More research on FITY
FITY technical analysis FITY TheEdge Score Compare against peers
Open full interactive analysis & DCF →